S&P 5007,709.96▼0.2% Nasdaq26,348.35▼0.1% Dow53,885.10▼0.8% Russell 2K3,001.55▼0.6% 10-Yr4.67%+5bp VIX15.15−0.66 WTI$78.07▲3.8% Gold$4,292.00▲1.1% EUR/USD1.152▼0.3% BTC$64,867▼0.1% Nikkei65,101▼1.8%
At close · Fri, Aug 7, 2026
Daily Market Updates.

US Markets

Home›US Markets›M&A & Deals›Samsung Biologics makes $1.8 billion all-cash bid for…

Samsung Biologics makes $1.8 billion all-cash bid for PolyPeptide

The offer values PolyPeptide at 1.46 billion Swiss francs, or about $1.8 billion, and is structured as an all-cash transaction.

Reported · Written up by our desk · M&A & Deals

Samsung Biologics has made an all-cash bid for Switzerland-based PolyPeptide Group, according to CNBC Markets. The proposed deal is for 1.46 billion Swiss francs, which CNBC World reported as equivalent to about $1.8 billion.

Samsung Biologics said the offer is 100% cash, reflecting a fully cash transaction structure for the acquisition.

← Newer storyTrump tells Carney Canada must do more on Ontario wildfire smoke

More like this

US MarketsCore Scientific and AMD expand data-center capacity via 15-year deals
US MarketsBerkshire resumes net stock buying after 14 quarters of selling
US MarketsComcast Business deploys private wireless for Smartlink at Annapolis HQ
US MarketsVictory Capital executive sells vested shares to cover tax liabilities
US MarketsSpaceX investor says firm sold his shares without notice

Sources

CNBC MarketsSamsung Biologics makes $1.8 billion all-cash offer for Switzerland's PolyPeptide Group
CNBC WorldSamsung Biologics makes $1.8 billion all-cash offer for Switzerland's PolyPeptide Group

Get the close, explained.

One email every trading day: what moved, why it moved, and what's on deck tomorrow. Read in 3 minutes.

Free. Unsubscribe anytime.